The therapeutic ability of the uncleavable variant of Sema3E (Uncl-Sema3E) was demonstrated in multiple tumour models where it acts as a novel inhibitor of tumour growth, metastasis, and angiogenesis (40). The gene discussed is UNC50; the disease is neoplasm.